Treatment of Thyrotropin-Secreting Pituitary Adenomas with Octreotide

Endocrine Journal

HIROYUKI MURABE¹  KAZUWA NAKAO¹  KYUZI KAMOI³  YOSHIKAZU SUZUKI⁴  AKIRA SHIMATSU² 

[1] Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine;Department of Laboratory Medicine, Kyoto University Graduate School of Medicine;Department of Medicine, Nagaoka Red Cross Hospital;Second Department of Internal Medicine, Hamamatsu Medical University

关键词: Thyrotropin-secreting pituitary adenoma;    α-Subunit;    Octreotide;    Tumor shrinkage;    Hyperthyroidism;    Tachyphylaxis;   

DOI  :  10.1507/endocrj.46.113

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(50)Cited-By(9)Five hyperthyroid patients with TSH-secreting pituitary adenoma were treated with octreotide. Acute administration of octreotide decreased plasma TSH levels in all patients (mean decrease, 50.6±14%). Treatment with octreotide (25-300μg/day) for 2-360 weeks resulted in reductions in plasma TSH and α-subunit levels in three patients, and serum free thyroxine levels were normalized with concomitant clinical improvements such as disappearance of excessive sweating, tachycardia and finger tremors. In two patients, plasma TSH and free thyroxine levels were initially decreased, but tachyphylaxis occurred 3 and 10 weeks after the initiation of therapy. Mild to marked shrinkage of the tumor was observed 2-50 weeks later in four patients. Shrinkage of the tumor seems to be reversible in one case. Frequent bowel movements and epigastric discomfort occurred in two patient. Somatostatin receptor subtype 2 (sst2) mRNAs were detected in two adenoma tissues studied by RT-PCR. Long-term treatment with octreotide is effective in controlling hyperthyroidism and tumor growth in patients with TSH-secreting pituitary adenoma.

【 授权许可】

Unknown